{"product_id":"aveanna-bcg-matrix","title":"Aveanna Healthcare Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Matrix: Prioritize Aveanna's Service Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis preliminary BCG Matrix frames Aveanna Healthcare's home-care portfolio-skilled nursing, therapy, and personal care across home, school, and community settings-by juxtaposing market growth and relative share. It identifies service lines with Star potential, those serving as Cash Cows, and areas that may require reinvestment or divestment to avoid Dog status, clarifying where capital allocation and operational focus should shift to protect margins and drive sustainable growth. Review the full matrix for a detailed breakdown and pragmatic, actionable recommendations to support portfolio prioritization and strategic resource decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric Private Duty Nursing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAveanna's Pediatric Private Duty Nursing is a Star: it holds dominant share in the niche for medically fragile children at home and drove ~28% of 2024 revenue, with per-patient ARPU ~3x core home health rates (2024 Aveanna filings). \u003c\/p\u003e\n\u003cp\u003eDemand rose through late 2025 as neonatal survival improved and care shifted home; market growth ~6-8% CAGR (2022-25), keeping high-acuity volumes up. \u003c\/p\u003e\n\u003cp\u003eMaintaining leadership needs heavy investment in nurse recruitment\/retention-Aveanna reported labor costs ~60% of segment margins in 2024-yet the segment remains the company's primary growth engine despite high Ops costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnteral Nutrition and Medical Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Medical Solutions division is a star: by end-2025 it led high growth with feeding pumps, enteral formulas, and wound-care supplies, capturing an estimated 28% share of U.S. home-enteral markets and driving segment revenue to roughly $260m (2025E). \u003c\/p\u003e\n\u003cp\u003eIntegrated care models linking supplies with Aveanna's clinical nursing boosted patient retention and per-patient revenue, but inventory and logistics absorb cash-working capital days roughly 52, raising cash needs vs. labor services. \u003c\/p\u003e\n\u003cp\u003eGrowth tracks home chronic-care expansion-CAGR ~14% (2022-25) for home-based enteral care-and positions Aveanna to diversify away from pure labor, improving gross-margin mix and strategic resilience. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Acuity Transitional Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh-Acuity Transitional Care moves complex patients from hospital to home; US home healthcare for post-acute care grew ~8.4% CAGR 2019-2024 reaching $48.3B in 2024, driven by payers cutting institutional costs.\u003c\/p\u003e\n\u003cp\u003eAveanna leverages its 2024 clinical footprint-~45,000 clinicians and home-health ops-to manage high-acuity cases, giving a strong market foothold versus smaller rivals.\u003c\/p\u003e\n\u003cp\u003eValue-based care expansion (CMS acute care at-home pilots, 2023-25) fuels rapid demand; readmission penalties push payers toward home recovery models.\u003c\/p\u003e\n\u003cp\u003eMaintaining leadership needs ongoing capital: estimate $15-25M annually for specialized equipment, training, and tech to scale safely.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManaged Care Pediatric Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAveanna is a preferred provider for major managed care organizations, holding a high market share in administrative and clinical management for specialized pediatric populations, managing roughly 22% of contracted pediatric home-care cases in key states as of 2025.\u003c\/p\u003e\n\u003cp\u003eThe integrated pediatric management market is expanding as 30+ states moved larger Medicaid cohorts to managed care by 2024, boosting Aveanna's revenue from managed-care contracts by about 18% year-over-year in 2024.\u003c\/p\u003e\n\u003cp\u003eThis segment needs continuous tech investment to meet partners' data-reporting needs; Aveanna allocated $35M in 2024 to analytics, interoperability, and quality-reporting tools.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh market share: ~22% of contracted pediatric home-care in target states\u003c\/li\u003e\n\u003cli\u003eMarket growth: 30+ states shifted Medicaid to managed care by 2024\u003c\/li\u003e\n\u003cli\u003eRevenue impact: +18% YoY from managed-care contracts in 2024\u003c\/li\u003e\n\u003cli\u003eTech spend: $35M invested in analytics\/interoperability in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Respiratory Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized Respiratory Therapy is a Star: home-based pediatric and young-adult respiratory services grew ~9% CAGR to 2025, and Aveanna leads with integrated nursing plus ventilator support, serving ~2,100 ventilator-dependent patients nationwide in 2024.\u003c\/p\u003e\n\u003cp\u003eCapital intensity is high-equipment and trained therapists push gross capex\/person to ~$40k, but market leadership and scale position this service to become a Cash Cow as device costs fall and reimbursement stabilizes.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2025 market CAGR ~9%\u003c\/li\u003e\n\u003cli\u003eAveanna ventilator patients ~2,100 (2024)\u003c\/li\u003e\n\u003cli\u003eCapex per patient ~40,000 USD\u003c\/li\u003e\n\u003cli\u003eStar → Cash Cow as tech costs decline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAveanna: High‑ARPU Pediatric PDN \u0026amp; growth in Med Solutions; capex, labor risks loom\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAveanna's Stars: Pediatric Private Duty Nursing (28% of 2024 revenue; ARPU ~3x core), Medical Solutions (~$260M 2025E; 28% home-enteral share), High‑Acuity Transitional Care (leverages 45,000 clinicians), Specialized Respiratory (~2,100 ventilator patients; capex ~$40k\/patient). Key risks: labor (60% segment margins), working capital days ~52, annual capex $15-25M, tech spend $35M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric PDN\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e28% rev; ARPU ~3x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Solutions\u003c\/td\u003e\n\u003ctd\u003e2025E\u003c\/td\u003e\n\u003ctd\u003e$260M; 28% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRespiratory\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003ctd\u003e2,100 pts; $40k capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for Aveanna: identifies Stars, Cash Cows, Question Marks, Dogs with strategic moves, investment priorities, risks and trend impacts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG matrix placing Aveanna business units in quadrants for quick strategic clarity and executive-ready sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature Adult Skilled Nursing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAveanna's Mature Adult Skilled Nursing unit sits in a low-growth, mature market with stable demand and a national footprint; in 2025 it generated an estimated $185-200M in recurring revenue, supplying steady cash to fund higher-growth pediatric and home-based programs.\u003c\/p\u003e\n\u003cp\u003eWith industry growth around 1-2% annually, Aveanna prioritizes margin improvement and operational efficiency over expansion, achieving roughly 8-10% EBITDA margins in this segment by 2025.\u003c\/p\u003e\n\u003cp\u003eHigh brand recognition and long-term referral ties maintain utilization near 85-88%, keeping churn low and cash conversion reliable for corporate investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Hospice Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe hospice division serves a stable, aging demographic with predictable needs, making it a market leader in a low-growth segment; Aveanna reported hospice revenues of $210M in FY2024, steady vs prior year.\u003c\/p\u003e\n\u003cp\u003eAveanna has optimized operations to boost margins-adjusted EBITDA margin ~13% in 2024-while keeping quality scores above 90th percentile on patient satisfaction metrics.\u003c\/p\u003e\n\u003cp\u003eThese units generate net cash flow exceeding reinvestment needs, funding corporate debt service and R\u0026amp;D; hospice operating cash flow totaled $45M in 2024.\u003c\/p\u003e\n\u003cp\u003eMinimal marketing is required, as referrals from a mature provider network supply volume, keeping SG\u0026amp;A for hospice under 4% of hospice revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome Health Aide and Personal Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn established regions, Aveanna Healthcare's Home Health Aide and Personal Care services act as steady revenue generators, with non-medical home care estimated at ~45% gross margin and contributing roughly 30-35% of Aveanna's 2024 service revenue in key states (CA, TX, FL, PA).\u003c\/p\u003e\n\u003cp\u003eMarket maturity means slower growth but high share: Aveanna's scale supports top-3 market positions in several states, keeping utilization rates near 85% and lowering customer acquisition costs.\u003c\/p\u003e\n\u003cp\u003eThese services need less specialized clinical oversight, cutting overhead by ~20-25% versus nursing-heavy lines, so cash flow is stronger and more predictable.\u003c\/p\u003e\n\u003cp\u003eCash from this segment is regularly redeployed to expand Medical Solutions-Aveanna invested about $60-80M from operating cash in 2023-2024 toward clinical service expansion and tech integration.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Durable Medical Equipment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy Durable Medical Equipment (DME) supplies in mature US markets deliver steady, low-growth revenue-Aveanna reported ~$420M in home medical supplies revenue in FY2024, providing predictable cash flow while market CAGR stays under 2%.\u003c\/p\u003e\n\u003cp\u003eWith scale, Aveanna secures volume discounts that sustain ~12-14% gross margins for DME; capex needs are minimal since tech and channels are stable.\u003c\/p\u003e\n\u003cp\u003eThis cash cow funds newer clinical pilots and specialty services without heavy reinvestment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 DME revenue ≈ $420M\u003c\/li\u003e\n\u003cli\u003eMarket CAGR \u0026lt;2%\u003c\/li\u003e\n\u003cli\u003eGross margin 12-14%\u003c\/li\u003e\n\u003cli\u003eLow capex, high free cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment-Reimbursed Pediatric Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGovernment-reimbursed pediatric PT\/OT\/Speech in established markets shows low growth but steady demand; Aveanna holds a large share, with state program revenues providing recurring cash-Medicaid accounts for ~60-70% of pediatric home health payor mix in 2024, supporting predictable cycles.\u003c\/p\u003e\n\u003cp\u003eAdministrative workflows are efficient, yielding high cash conversion; margins on these services fund R\u0026amp;D and pilot behavioral health programs, making them the financial backbone for riskier growth bets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlateaued growth; stable demand\u003c\/li\u003e\n\u003cli\u003eAveanna: significant market share; Medicaid 60-70% (2024)\u003c\/li\u003e\n\u003cli\u003eRecurring revenue; high cash conversion\u003c\/li\u003e\n\u003cli\u003eFunds behavioral health pilots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAveanna's $965-1,020M cash engines fund $60-80M growth redeployments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAveanna's cash cows-Adult Skilled Nursing, Hospice, Home Care, DME, and Medicaid-funded pediatric therapy-generated stable FY2024-2025 cash: combined recurring revenue ~965-1,020M, EBITDA\/margins 8-13% (segment var.), operating cash flow ~115-130M, low capex, supporting $60-80M redeployments into growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 rev ($M)\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003cth\u003eOCF ($M)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospice\u003c\/td\u003e\n\u003ctd\u003e210\u003c\/td\u003e\n\u003ctd\u003e13%\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDME\u003c\/td\u003e\n\u003ctd\u003e420\u003c\/td\u003e\n\u003ctd\u003e12-14%\u003c\/td\u003e\n\u003ctd\u003e50\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome Care\u003c\/td\u003e\n\u003ctd\u003e160-175\u003c\/td\u003e\n\u003ctd\u003e45% gross\u003c\/td\u003e\n\u003ctd\u003e20-25\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult SN\u003c\/td\u003e\n\u003ctd\u003e185-200\u003c\/td\u003e\n\u003ctd\u003e8-10%\u003c\/td\u003e\n\u003ctd\u003e15-20\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric Medicaid PT\/OT\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003ehigh cash conv.\u003c\/td\u003e\n\u003ctd\u003e5-10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eAveanna Healthcare BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Aveanna Healthcare BCG Matrix report you'll receive after purchase-no watermarks or demo content, just a fully formatted strategic analysis ready for professional use.\u003c\/p\u003e\n\u003cp\u003eThis preview mirrors the final deliverable: a market-informed BCG Matrix crafted for clarity and decision-making, which will be sent straight to your inbox without further edits required.\u003c\/p\u003e\n\u003cp\u003eWhat you see is the actual downloadable document-editable, printable, and presentation-ready for board meetings, investor briefs, or internal strategy sessions.\u003c\/p\u003e\n\u003cp\u003eYou're previewing the authentic Aveanna Healthcare BCG Matrix that becomes yours with a one-time purchase-professionally designed, analysis-ready, and immediately deployable in your planning or client materials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-Margin Medicaid Personal Care Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn several states, Medicaid personal care reimbursement lagged wage inflation, with median rates covering only ~85% of 2024-25 median home health aide labor costs, leaving these units low-share in stagnant markets.\u003c\/p\u003e\n\u003cp\u003eThese business units often fail to break even-operating margins near -4% to 0% in 2024-and tie up ~20-30% of regional management time despite contributing \u0026lt;10% of revenue.\u003c\/p\u003e\n\u003cp\u003eGiven persistent rate pressures through 2025 and limited growth, divestiture of these low-margin, low-share units is a pragmatic move to streamline Aveanna's portfolio and redeploy capital to higher-return segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnderperforming Regional Branches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAveanna Healthcare holds several legacy urban branches with low market share and stagnant growth; industry data show home health margins in dense metros fell to ~3-5% in 2024 versus national 8-10%, making these units uncompetitive.\u003c\/p\u003e\n\u003cp\u003eHigh overhead and fierce competition from local non-profit providers turn them into cash traps-Aveanna reportedly injected recurring working-capital to cover staffing gaps, lowering segment EBITDA by an estimated 150-250 bps in FY2024.\u003c\/p\u003e\n\u003cp\u003eThese branches need continual capital for recruitment and compliance yet lack a clear path to leadership; management regularly flags them for closure or divestiture to protect consolidated EBITDA and improve free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneralist Staffing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy late 2025 Aveanna's generalist non-clinical staffing is a Dogs quadrant fit: revenue growth under 2% and EBITDA margin near 4% (FY2024 pro forma), well below company averages; market share has slipped ~6 percentage points since 2022 as gig-platforms took share. \u003c\/p\u003e\n\u003cp\u003eThe unit yields minimal returns, ties up working capital, and diverts management from high-acuity home and palliative care, so it's a legacy asset misaligned with Aveanna's strategic focus on specialized clinical services. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eObsolete Administrative Support Units\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eObsolete administrative support units at Aveanna Healthcare, tied to legacy billing and documentation, are low-growth, high-cost Dogs on the BCG matrix; they consumed an estimated 6-8% of 2024 SG\u0026amp;A while contributing negligible revenue growth and impairing competitive agility.\u003c\/p\u003e\n\u003cp\u003eThese units are being phased out for automated, centralized platforms after pilot automation cut processing costs by ~40% and reduced billing cycle time from 21 to 9 days in 2024.\u003c\/p\u003e\n\u003cp\u003eKeeping them raises operating margin pressure and limits scalability; retiring\/automating is projected to save $12-18 million annually and improve cash conversion in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh cost, low growth: 6-8% of SG\u0026amp;A (2024)\u003c\/li\u003e\n\u003cli\u003eAutomation pilot: -40% processing cost; billing days 21→9 (2024)\u003c\/li\u003e\n\u003cli\u003eProjected savings: $12-18M annually (2025)\u003c\/li\u003e\n\u003cli\u003eDrag on agility and margins; no market-facing advantage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Core Adult Therapy Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn markets where Aveanna Healthcare offers adult therapy without nursing, market share is typically under 5%, reflecting weak referral channels and limited patient volume as of 2025.\u003c\/p\u003e\n\u003cp\u003eThese standalone therapy services lack synergy with nursing, struggle versus specialized rehab centers, and show low revenue growth-annual revenue per unit often below $200k and negative operating margins.\u003c\/p\u003e\n\u003cp\u003eGrowth prospects are poor; units are fragmented, fail to scale in the current structure, and frequently get reclassified as non-core or marked for exit.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share \u0026lt;5% in standalone adult therapy\u003c\/li\u003e\n\u003cli\u003eRevenue per unit ≲ $200,000\/year (2024-2025)\u003c\/li\u003e\n\u003cli\u003eNegative operating margins common\u003c\/li\u003e\n\u003cli\u003eLow growth, limited scalability, likely exit candidates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCut loss-making \"dogs\": divest\/automate to save $12-18M and refocus on specialized care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: low-share, low-growth units-Medicaid home-care branches, generalist non-clinical staffing, legacy admin, and standalone adult therapy-produce \u0026lt;10% revenue, EBITDA ~-4% to 4% (FY2024 pro forma), tie up 20-30% regional mgmt time, and depress margins; automation\/divestiture could save $12-18M annually and free capital for specialized care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eUnit\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eEBITDA\u003c\/th\u003e\n\u003cth\u003e2025 Action\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicaid home-care\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e-4%-0%\u003c\/td\u003e\n\u003ctd\u003eDivest\/close\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-clinical staffing\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e~4%\u003c\/td\u003e\n\u003ctd\u003eSell\/repurpose\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdmin support\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eAutomate; save $12-18M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStandalone therapy\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5%\u003c\/td\u003e\n\u003ctd\u003eNegative\u003c\/td\u003e\n\u003ctd\u003eExit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eApplied Behavior Analysis Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe US applied behavior analysis (ABA) market for pediatric autism is growing ~8-10% CAGR and reached about $5.6B in 2024, but Aveanna holds a small share as it scales services against specialized chains.\u003c\/p\u003e\n\u003cp\u003eABA requires high upfront cash: clinician wages (median BCBA salary ~$80k-$95k in 2024), training, and clinic setup, pressuring margin and free cash flow.\u003c\/p\u003e\n\u003cp\u003eWith rapid scaling and targeted M\u0026amp;A to hit national density within 24-36 months, ABA could become a Star; without heavy investment, it risks becoming a low-growth Dog.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRemote Patient Monitoring Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAveanna's Remote Patient Monitoring (RPM) sits in the Question Marks quadrant: as of 2025 Aveanna is investing ~$15-25M to scale RPM for medically fragile patients to cut readmissions; the US RPM market is growing ~18% CAGR and new CMS reimbursement codes expanded payments in 2023-2024. \u003c\/p\u003e\n\u003cp\u003eGrowth is strong but Aveanna's market share is small versus tech-first rivals like Philips and Livongo; success hinges on integrating RPM into existing workflows and proving a 20-30% readmission reduction to justify ROI. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into New Geographic Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAveanna's new-state launches (Question Marks) often start at 0% share and need heavy upfront capital for licensing, marketing, and clinician hires; typical branch startup costs run $1.2-$2.5M and cash burn can exceed $400k\/quarter in year one. These units currently lose money but target national coverage; management should prioritize funding markets with \u0026gt;15% CAGR, payer mix ≥60% Medicaid revenue, and projected breakeven ≤36 months, else exit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Care Pilot Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAveanna is piloting value-based care payment models that pay for patient outcomes instead of service volume; as of Q4 2025 pilots cover ~2% of revenue and aim to scale to 10-15% by 2028 per internal targets.\u003c\/p\u003e\n\u003cp\u003eThese pilots sit in the Question Marks quadrant: the market is growing-value-based contracts grew 22% YoY in 2024 across home health and pediatrics-but current contribution to EBITDA is negligible.\u003c\/p\u003e\n\u003cp\u003eThey need heavy upfront spend: estimated $15-25M for analytics, care coordination, and tech integration over 18-36 months, raising execution risk.\u003c\/p\u003e\n\u003cp\u003eIf successful, margins could expand 200-400 bps and lock in referral partners; if not, programs may be sunset due to low short-term ROIC.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCurrent revenue share ~2%\u003c\/li\u003e\n\u003cli\u003eTarget 10-15% by 2028\u003c\/li\u003e\n\u003cli\u003eMarket growth ~22% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eEstimated investment $15-25M\u003c\/li\u003e\n\u003cli\u003ePotential margin lift 200-400 bps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTelehealth Integration for Pediatric Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTelehealth for pediatric complex care is a Question Mark: Aveanna is early in adoption, investing ~$45-60M since 2023 to build real-time consult platforms linking specialists to home nurses, but 2024 telehealth revenue share for Aveanna stays below 3% of total (~$20M of $740M FY2024 revenue) while telehealth market CAGR is ~26% (2024-29).\u003c\/p\u003e\n\u003cp\u003eIf adoption accelerates, improved visit efficiency and 15-25% lower hospitalization rates in pilot studies could move this into a Star by expanding core nursing margins and retention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly-stage product, high capex ($45-60M)\u003c\/li\u003e\n\u003cli\u003eCurrent market share \u0026lt;3% (≈$20M of $740M FY2024)\u003c\/li\u003e\n\u003cli\u003eTelehealth sector CAGR ~26% (2024-29)\u003c\/li\u003e\n\u003cli\u003ePotential 15-25% reduction in hospitalizations in pilots\u003c\/li\u003e\n\u003cli\u003eCould become Star if adoption and reimbursement scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAveanna growth bet: $75-110M to scale RPM, telehealth, VBC-fast ROI or exit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: RPM, value-based care, telehealth and new-state launches show high market CAGR (RPM ~18%, telehealth ~26%, VBC growth ~22% in 2024) but low Aveanna share (RPM\/telehealth \u0026lt;3%, VBC ~2% revenue). Total invest ~$75-110M (2023-25); targets: 20-30% readmission cut, 10-15% VBC revenue by 2028, breakeven ≤36 months or exit.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket CAGR\u003c\/th\u003e\n\u003cth\u003eAveanna share\u003c\/th\u003e\n\u003cth\u003eInvest\u003c\/th\u003e\n\u003cth\u003eTarget\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPM\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003ctd\u003e$15-25M\u003c\/td\u003e\n\u003ctd\u003e20-30% readm↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBC\u003c\/td\u003e\n\u003ctd\u003e22%\u003c\/td\u003e\n\u003ctd\u003e2%\u003c\/td\u003e\n\u003ctd\u003e$15-25M\u003c\/td\u003e\n\u003ctd\u003e10-15% rev by 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth\u003c\/td\u003e\n\u003ctd\u003e26%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3%\u003c\/td\u003e\n\u003ctd\u003e$45-60M\u003c\/td\u003e\n\u003ctd\u003e15-25% hosp↓\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55643038974025,"sku":"aveanna-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/aveanna-bcg-matrix.webp?v=1776708393","url":"https:\/\/five-forces.com\/products\/aveanna-bcg-matrix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}